Figure 2

Endpoint events in both groups over 5 years. There was no significant difference in total mortality, cardiovascular mortality, or re-hospitalisation for a protocol-specific cardiovascular cases between patients with (+) anti-AT₁-AR and (−) anti-AT₁-AR (all P > 0.05).